Myasthenia Gravis (MG) is a chronic autoimmune neuromuscular disorder that affects the transmission of nerve impulses to muscles. It is characterized by muscle weakness and fatigue, which can be exacerbated by physical activity or stress. MG is a rare disorder, with an estimated prevalence of 20-50 cases per 100,000 people. The Myasthenia Gravis market within the context of Allergy and Immunology is focused on the development of treatments and therapies to improve the quality of life of those affected by the disorder. These treatments include immunosuppressants, anticholinesterase drugs, and thymectomy. Additionally, research is being conducted to develop novel therapies, such as monoclonal antibodies and gene therapy. Companies in the Myasthenia Gravis market include AbbVie, Alexion Pharmaceuticals, Astellas Pharma, Biogen, F. Hoffmann-La Roche, GlaxoSmithKline, Merck & Co., Novartis, Pfizer, and Sanofi. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
